Table of Contents
ISRN Oncology
Volume 2012, Article ID 947831, 5 pages
http://dx.doi.org/10.5402/2012/947831
Clinical Study

Parameters of Blood Count and Tumor Markers in Patients with Borderline Ovarian Tumors: A Retrospective Analysis and Relation to Staging

1Discipline of Gynecology and Obstetrics, Oncological Research Institute (IPON), Federal University of Triângulo Mineiro, 38025-440 Uberaba, MG, Brazil
2Discipline of Pharmacology, Federal University of Triângulo Mineiro, 38025-440 Uberaba, MG, Brazil

Received 16 January 2012; Accepted 20 February 2012

Academic Editor: A. E. Bilsland

Copyright © 2012 Rosekeila Simões Nomelini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Scully, “Common epithelial tumors of borderline malignancy (carcinomas of low malignant potential),” Bulletin du Cancer, vol. 69, no. 3, pp. 228–238, 1982. View at Google Scholar · View at Scopus
  2. Y. Katsube, J. W. Berg, and S. G. Silverberg, “Epidemiologic pathology of ovarian tumors: a histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 December 1979,” International Journal of Gynecological Pathology, vol. 1, no. 1, pp. 3–16, 1982. View at Google Scholar · View at Scopus
  3. C. G. Julian and J. D. Woodruff, “The biologic behavior of low-grade papillary serous carcinoma of the ovary,” Obstetrics and Gynecology, vol. 40, no. 6, pp. 860–867, 1972. View at Google Scholar
  4. J. F. Leake, J. L. Currie, N. B. Rosenshein, and J. D. Woodruff, “Long-term follow-up of serous ovarian tumors of low malignant potential,” Gynecologic Oncology, vol. 47, no. 2, pp. 150–158, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Tropé and J. Kærn, “Prognosis and management of borderline tumours of the ovary,” Current Opinion in Obstetrics and Gynecology, vol. 8, no. 1, pp. 12–16, 1996. View at Google Scholar
  6. H. C. Taylor, “Malignant and semimalignant tumors of the ovary,” Surgery, Gynecology & Obstetrics, vol. 48, pp. 204–230, 1929. View at Google Scholar
  7. C. J. Link Jr, E. Kohn, and E. Reed, “The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects,” Gynecologic Oncology, vol. 60, no. 3, pp. 347–354, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Tulpin, R. Rouzier, O. Morel, C. Malartic, E. Daraï, and E. Barranger, “Borderline ovarian tumors: an update,” Gynecologie Obstetrique Fertilite, vol. 36, no. 4, pp. 422–429, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Tropé, B. Davidson, T. Paulsen, V. M. Abeler, and J. Kaern, “Diagnosis and treatment of borderline ovarian neoplasms "the state of the art",” European Journal of Gynaecological Oncology, vol. 30, no. 5, pp. 471–482, 2009. View at Google Scholar · View at Scopus
  10. J. Ren, J. Y. Lou, H. Liu et al., “Clinicopathologic features of 234 cases with borderline ovarian tumors,” Zhonghua fu Chan ke Zahi, vol. 44, no. 2, pp. 116–120, 2009. View at Google Scholar
  11. E. F. C. Murta, C. S. Da Silva, R. A. S. Gomes, B. M. Tavares-Murta, and A. L. K. O. Melo, “Ultrasonographic criteria and tumor marker assay are good procedures for the diagnosis of ovarian neoplasia in preselected outpatients,” European Journal of Gynaecological Oncology, vol. 25, no. 6, pp. 707–712, 2004. View at Google Scholar
  12. E. F. C. Murta and R. S. Nomelini, “Early diagnosis and predictors of malignancy of adnexal masses,” Current Opinion in Obstetrics and Gynecology, vol. 18, no. 1, pp. 14–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. I. Cadron, F. Amant, T. Van Gorp, P. Neven, K. Leunen, and I. Vergote, “The management of borderline tumours of the ovary,” Current Opinion in Oncology, vol. 18, no. 5, pp. 488–493, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Kokawa, Y. Mikami, H. Sakata et al., “Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years' experience in the Kinki District of Japan (1990-2006),” European Journal of Gynaecological Oncology, vol. 30, no. 2, pp. 155–161, 2009. View at Google Scholar · View at Scopus
  15. S.-J. Chang, H.-S. Ryu, K.-H. Chang, S. C. Yoo, and J. H. Yoon, “Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors,” Acta Obstetricia et Gynecologica Scandinavica, vol. 87, no. 4, pp. 476–481, 2008. View at Publisher · View at Google Scholar
  16. B. M. Tavares-Murta, M. A. Mendonça, N. L. Duarte et al., “Systemic leukocyte alterations are associated with invasive uterine cervical cancer,” International Journal of Gynecological Cancer, vol. 20, no. 7, pp. 1154–1159, 2010. View at Publisher · View at Google Scholar
  17. R. S. Nomelini, A. S. L. Neto, K. A. Capuci, B. M. T. Murta, and E. F. C. Murta, “Relationship between plasma glucose levels and malignant uterine cervical neoplasias,” Clinical Medicine Insights, vol. 5, pp. 77–82, 2011. View at Publisher · View at Google Scholar
  18. K. Münstedt, M. Kovacic, M. Zygmunt, and R. von Georgi, “Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer,” International Journal of Oncology, vol. 23, no. 3, pp. 837–843, 2003. View at Google Scholar
  19. M. H. R. Eichbaum, L. M. E. Weiss, T. Bruckner et al., “Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer,” Medical Science Monitor, vol. 15, no. 4, pp. CR156–CR163, 2009. View at Google Scholar · View at Scopus
  20. K. Pongsanon, M. Benjapibal, and I. Ruengkhachorn, “Prognostic significance of hemoglobin levels in patients with primary epithelial ovarian carcinoma undergoing platinumbased chemotherapy,” Asian Pacific Journal of Cancer Prevention, vol. 12, no. 1, pp. 131–136, 2011. View at Google Scholar
  21. M. Bryne, G. E. Eide, R. Lilleng, F. Langmark, P. S. Thrane, and E. Dabelsteen, “A multivariate study of the prognosis of oral squamous cell carcinomas: are blood group and hemoglobin new prognostic factors?” Cancer, vol. 68, no. 9, pp. 1994–1998, 1991. View at Google Scholar · View at Scopus
  22. M. den Ouden, J. M. H. Ubachs, J. E. G. M. Stoot, and J. W. J. Van Wersch, “Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 72, no. 1, pp. 73–77, 1997. View at Publisher · View at Google Scholar
  23. A. G. J. Van der Zee, E. M. J. de Cuyper, P. C. Limburg et al., “Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts,” Cancer, vol. 75, no. 4, pp. 1004–1009, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Macciò, C. Madeddu, D. Massa et al., “Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia,” Blood, vol. 106, no. 1, pp. 362–367, 2005. View at Publisher · View at Google Scholar
  25. M. J. A. Engelen, H. W. A. de Bruijn, H. Hollema et al., “Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors,” Gynecologic Oncology, vol. 78, no. 1, pp. 16–20, 2000. View at Publisher · View at Google Scholar
  26. E. Kolwijck, C. M. G. Thomas, J. Bulten, and L. F. A. G. Massuger, “Preoperative CA-125 levels in 123 patients b with borderline ovarian tumors a retrospective analysis and review of the literature,” International Journal of Gynecological Cancer, vol. 19, no. 8, pp. 1335–1338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. T. I. Wu, C. L. Lee, M. Y. Wu et al., “Prognostic factors predicting recurrence in borderline ovarian tumors,” Gynecologic Oncology, vol. 114, no. 2, pp. 237–241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. E. V. S. Høgdall, L. Christensen, S. K. Kjaer et al., “Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA'ovarian cancer study,” Pathology, vol. 40, no. 5, pp. 487–492, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Muramatsu, M. Mukai, S. Sato et al., “Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer,” Oncology Reports, vol. 14, no. 4, pp. 861–865, 2005. View at Google Scholar · View at Scopus